Literature DB >> 19758639

Impact of urine sodium on urine risk factors for calcium oxalate nephrolithiasis.

Brian H Eisner1, Michael L Eisenberg, Marshall L Stoller.   

Abstract

PURPOSE: Increased sodium intake is thought to promote nephrolithiasis by dietary sodium hypercalciuric effects. However, equivocal data exist on whether increased urine sodium actually increases the nephrolithiasis risk. We examined the relationship between urine sodium and urine risk factors for nephrolithiasis.
MATERIALS AND METHODS: We retrospectively reviewed the records of 880 patients evaluated at a metabolic stone clinic to determine the relationship between urine sodium and urine calcium, volume and calcium oxalate supersaturation. Patients were separated into sodium excretion quintiles. Tests of linear trend were performed by examining the linear contrast in coefficients and using Cuzick's nonparametric linear trend test. Multivariate linear regression with urine sodium as a continuous variable was done to assess the relationship between urine sodium and other urine variables.
RESULTS: Tests of linear trend showed that urine calcium and volume increased with increasing urine sodium (each p <0.01) but urine calcium oxalate supersaturation decreased with increasing urine sodium (p <0.01). Multivariate linear regression was adjusted for age, sex, body mass index and urine constituents. Urine sodium was positively associated with urine calcium (beta = 0.28, 95% CI 0.15 to 0.41, p <0.001) but negatively associated with urine calcium oxalate supersaturation (beta = -0.013, 95% CI -0.016 to -0.011, p <0.001). There was a trend toward a positive association of urine sodium and volume (beta = 0.001, 95% CI -0.00019 to 0.002, p = 0.10).
CONCLUSIONS: Increasing urine sodium does not appear to increase the risk of calcium oxalate nephrolithiasis. Global sodium restriction may not necessarily alter the risk of stone formation, ie cause changes in calcium oxalate urine supersaturation, in patients with a history of nephrolithiasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19758639     DOI: 10.1016/j.juro.2009.07.014

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Oxidative stress and nephrolithiasis: a comparative pilot study evaluating the effect of pomegranate extract on stone risk factors and elevated oxidative stress levels of recurrent stone formers and controls.

Authors:  Chad R Tracy; Jonathan R Henning; Mark R Newton; Michael Aviram; M Bridget Zimmerman
Journal:  Urolithiasis       Date:  2014-08-02       Impact factor: 3.436

2.  Spectroscopic Characterization of Urinary Stones Richening with Calcium Oxalate.

Authors:  Abdallah A Shaltout; Maram M Dabi; Sameh I Ahmed; Ahmed S Al-Ghamdi; Essam Elnagar; Roshdi Seoudi
Journal:  Biol Trace Elem Res       Date:  2020-10-10       Impact factor: 3.738

3.  Does the mineral content of tap water correlate with urinary calculus composition?

Authors:  Kirolos G F T Michael; Sarah Michael; Ehab Abusada; Shalom J Srirangam; Andreas Bourdoumis; Raveendra Surange
Journal:  Urolithiasis       Date:  2022-08-28       Impact factor: 2.861

4.  Metabolic disturbances in Chinese children with urolithiasis: a single center report.

Authors:  Dong Yang; Hans-Göran Tiselius; Chuangxin Lan; Dong Chen; Kang Chen; Lili Ou; Yang Liu; Shaohong Xu; Guohua Zeng; Ming Lei; Wenqi Wu
Journal:  Urolithiasis       Date:  2016-08-10       Impact factor: 3.436

5.  Preventive fluid and dietary therapy for urolithiasis: An appraisal of strength, controversies and lacunae of current literature.

Authors:  Mayank Mohan Agarwal; Shwaran K Singh; Ravimohan Mavuduru; Arup K Mandal
Journal:  Indian J Urol       Date:  2011-07

6.  Effect of vitamin D supplementation on 24-hour urine calcium in patients with calcium Urolithiasis and vitamin D deficiency.

Authors:  Maryam Taheri; Sanaz Tavasoli; Fatemeh Shokrzadeh; Fahimeh Bagheri Amiri; Abbas Basiri
Journal:  Int Braz J Urol       Date:  2019 Mar-Apr       Impact factor: 1.541

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.